The chart is not accessible to screen readers. Please switch to the table view to access the data.
Chiesi is one of the leading Italian pharmaceutical companies. Over the last few years, the revenue generated by Chiesi steadily increased, peaking in 2023 at over *** euros. Correspondingly, the number of employees and the investments in research and development grew.
 Therapeutic areas
Chiesi was founded in 1935, but the process of internationalization of the brand did not start until the late ***. In the same period, Clenil – one of the most successful products developed by this firm - was launched on the market. Clenil is used to treat issues of the respiratory system such as asthma or airway inflammation. Not surprisingly, the company is now specialized in the production of drugs for the respiratory system as well as in the manufacture of medications for primary care, neonatology and rare diseases.  
Internationalization
The internationalization activities became more intense starting from the late ***, when the Group opened many affiliates worldwide. Currently, the importance of Chiesi on an international scale is also confirmed by its presence in the ranking of the leading Italian pharmaceutical companies in 2021.
Log in or register to access precise data.
* For commercial use only
Basic Account
Starter Account
The statistic on this page is a Premium Statistic and is included in this account.
Professional Account
1 All prices do not include sales tax. The account requires an annual contract and will renew after one year to the regular list price.
Industry overview
Key players
International trade
Research and development
Outlook
* For commercial use only
Basic Account
Starter Account
The statistic on this page is a Premium Statistic and is included in this account.
Professional Account
1 All prices do not include sales tax. The account requires an annual contract and will renew after one year to the regular list price.
